propranolol has been researched along with Alcohol Abuse in 57 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the beta-adrenergic blocking agent propranolol was tested on positional tremor occurring during acute alcohol withdrawal using a double-blind crossover method and electrical recording of tremor amplitude and frequency." | 9.04 | Effect of propranolol on acute withdrawal tremor in alcoholic patients. ( Larsen, A; Teräväinen, H, 1976) |
| "Alcohol drinking following propranolol treatment was variable, but the combination of propranolol + prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone." | 7.80 | Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. ( Beckwith, LE; Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2014) |
| "Antiarrhythmic effects of cordarone, ethacizine, and obsidan were evaluated in 30 patients with chronic alcoholism in whom premature ventricular contractions were recorded at a rate of at least of 5 per minute by 30-minute ECG monitoring when they were admitted to a narcologic hospital, having the alcohol withdrawal syndrome." | 7.68 | [Effectiveness of single intravenous administration of cordarone, ethacizine and obsidan in ventricular extrasystole in patients with chronic alcoholism during withdrawal]. ( Gorgaslidze, AG; Karaush, AP; Smetnev, AS, 1991) |
| "The pattern of cardiac arrhythmias and their treatment, by propranolol and chlordiazepoxide, during the first 48 hr of alcohol withdrawal has been studied." | 7.66 | Propranolol and chlordiazepoxide effects on cardiac arrhythmias during alcohol withdrawal. ( Jacob, MS; MacLeod, SM; Sellers, EM; Ti, TY; Zilm, DH, 1980) |
| "The effect of the beta-adrenergic blocking agent propranolol was tested on positional tremor occurring during acute alcohol withdrawal using a double-blind crossover method and electrical recording of tremor amplitude and frequency." | 5.04 | Effect of propranolol on acute withdrawal tremor in alcoholic patients. ( Larsen, A; Teräväinen, H, 1976) |
| "Alcohol drinking following propranolol treatment was variable, but the combination of propranolol + prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone." | 3.80 | Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone. ( Beckwith, LE; Froehlich, JC; Kincaid, CL; Rasmussen, DD, 2014) |
| "Antiarrhythmic effects of cordarone, ethacizine, and obsidan were evaluated in 30 patients with chronic alcoholism in whom premature ventricular contractions were recorded at a rate of at least of 5 per minute by 30-minute ECG monitoring when they were admitted to a narcologic hospital, having the alcohol withdrawal syndrome." | 3.68 | [Effectiveness of single intravenous administration of cordarone, ethacizine and obsidan in ventricular extrasystole in patients with chronic alcoholism during withdrawal]. ( Gorgaslidze, AG; Karaush, AP; Smetnev, AS, 1991) |
| "The pattern of cardiac arrhythmias and their treatment, by propranolol and chlordiazepoxide, during the first 48 hr of alcohol withdrawal has been studied." | 3.66 | Propranolol and chlordiazepoxide effects on cardiac arrhythmias during alcohol withdrawal. ( Jacob, MS; MacLeod, SM; Sellers, EM; Ti, TY; Zilm, DH, 1980) |
| "Propranolol is a nonselective beta-adrenergic receptor antagonist." | 2.94 | Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial. ( Arbes, SJ; Campbell, JH; Di Giosia, M; Fillingim, RB; Hadgraft, H; Herman-Giddens, M; James, R; Lim, PF; Ohrbach, R; Ribeiro-Dasilva, M; Slade, GD; Tchivileva, IE; Willis, J, 2020) |
| "Propranolol treatment had no effect on consolidation of extinction learning, but impaired reconsolidation of self-administration." | 1.48 | Noradrenergic β-receptor antagonism in the basolateral amygdala impairs reconsolidation, but not extinction, of alcohol self-administration: Intra-BLA propranolol impairs reconsolidation of alcohol self-administration. ( Chesworth, R; Corbit, LH, 2018) |
| "Following development of alcohol dependence, rats exhibit hypersensitivity to the suppressive effects of propranolol on operant alcohol-reinforced responding." | 1.36 | Effects of β-adrenoceptor antagonists on alcohol drinking by alcohol-dependent rats. ( Gilpin, NW; Koob, GF, 2010) |
| "Propranolol alone was more effective than either chlordiazepoxide or a combination of chlordiazepoxide and propranolol in alleviating the symptoms of the alcohol withdrawal syndrome." | 1.26 | Comparative efficacy of propranolol and chlordiazepoxide in alcohol withdrawal. ( Degani, NC; Sellers, EM; Zilm, DH, 1977) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 45 (78.95) | 18.7374 |
| 1990's | 4 (7.02) | 18.2507 |
| 2000's | 1 (1.75) | 29.6817 |
| 2010's | 5 (8.77) | 24.3611 |
| 2020's | 2 (3.51) | 2.80 |
| Authors | Studies |
|---|---|
| De Oliveira Sergio, T | 1 |
| Wean, S | 1 |
| Katner, SN | 1 |
| Hopf, FW | 1 |
| Tchivileva, IE | 1 |
| Hadgraft, H | 1 |
| Lim, PF | 1 |
| Di Giosia, M | 1 |
| Ribeiro-Dasilva, M | 1 |
| Campbell, JH | 1 |
| Willis, J | 1 |
| James, R | 1 |
| Herman-Giddens, M | 1 |
| Fillingim, RB | 1 |
| Ohrbach, R | 1 |
| Arbes, SJ | 1 |
| Slade, GD | 1 |
| Díaz-Fontenla, F | 1 |
| Castillo-Pradillo, M | 1 |
| Díaz-Gómez, A | 1 |
| Ibañez-Samaniego, L | 1 |
| Gancedo, P | 1 |
| Guzmán-de-Villoria, JA | 1 |
| Fernández-García, P | 1 |
| Bañares-Cañizares, R | 1 |
| García-Martínez, R | 1 |
| Haass-Koffler, CL | 1 |
| Swift, RM | 1 |
| Leggio, L | 1 |
| Chesworth, R | 1 |
| Corbit, LH | 1 |
| Rasmussen, DD | 1 |
| Beckwith, LE | 1 |
| Kincaid, CL | 1 |
| Froehlich, JC | 1 |
| Levin, J | 1 |
| Mehrkens, J | 1 |
| Gerbes, A | 1 |
| Bötzel, K | 1 |
| Gilpin, NW | 1 |
| Koob, GF | 1 |
| Zawad, JS | 1 |
| Brown, FC | 1 |
| Obukhov, GA | 1 |
| Andreas, K | 1 |
| Fischer, HD | 1 |
| Schmidt, J | 1 |
| Ségal, A | 1 |
| Segel, LD | 1 |
| Mason, DT | 1 |
| Ward, K | 1 |
| Potamianos, G | 1 |
| Peters, TJ | 1 |
| Petersen, DR | 1 |
| Hjelle, JJ | 1 |
| Nygren, A | 1 |
| Sundblad, L | 1 |
| Zilm, DH | 5 |
| Jacob, MS | 1 |
| MacLeod, SM | 3 |
| Sellers, EM | 7 |
| Ti, TY | 1 |
| Hicks, R | 1 |
| Dysken, MW | 1 |
| Davis, JM | 1 |
| Lesser, J | 1 |
| Ripeckyj, A | 1 |
| Lazarus, L | 1 |
| Carlsson, C | 5 |
| Hemmingsen, R | 2 |
| Holm-Jensen, J | 1 |
| Trojaborg, W | 1 |
| Worner, TM | 1 |
| Wu, WJ | 1 |
| Pruett, SB | 1 |
| Degani, NC | 2 |
| French, SW | 1 |
| Palmer, DS | 1 |
| Wiggers, KD | 1 |
| Lee, SP | 1 |
| Tasman-Jones, C | 1 |
| Wattie, WJ | 1 |
| Ganda, OP | 1 |
| Sawin, CT | 1 |
| Iber, F | 1 |
| Glennon, JA | 1 |
| Mitchell, ML | 1 |
| Schoenen, J | 1 |
| Delwaide, PJ | 1 |
| Hunt, GP | 1 |
| Overstreet, DH | 1 |
| Frecker, RC | 1 |
| Kunov, H | 1 |
| Barry, DI | 1 |
| Hertz, MM | 1 |
| Klinken, L | 1 |
| Robertson, CC | 1 |
| Teräväinen, H | 1 |
| Larsen, A | 1 |
| Fasth, BG | 2 |
| Davis, FT | 1 |
| Hage, J | 1 |
| Jensen, K | 1 |
| Silfverskiöld, B | 1 |
| Karanjia, ND | 1 |
| Widdison, AL | 1 |
| Lutrin, FJ | 1 |
| Chang, YB | 1 |
| Reber, HA | 1 |
| Karaush, AP | 1 |
| Gorgaslidze, AG | 1 |
| Smetnev, AS | 1 |
| Given, MB | 1 |
| Longenecker, GL | 1 |
| Tyrer, P | 1 |
| Goodwin, JF | 1 |
| Whitlock, FA | 1 |
| Price, J | 1 |
| Jefferson, JW | 1 |
| Gallant, DM | 1 |
| Swanson, WC | 1 |
| Guerrero-Figueroa, R | 1 |
| Mendelson, JH | 1 |
| Rossi, AM | 1 |
| Bernstein, JG | 1 |
| Kuehnle, J | 1 |
| Schreiber, SS | 1 |
| Briden, K | 1 |
| Oratz, M | 1 |
| Rothschild, MA | 1 |
| Drew, LR | 1 |
| Moon, JR | 1 |
| Buchanan, FH | 1 |
| Castan, R | 1 |
| Johansson, T | 1 |
| Rösch, J | 1 |
| Gray, RK | 1 |
| Grollman, JH | 1 |
| Ross, G | 1 |
| Steckel, RJ | 1 |
| Weiner, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Erenumab as a Therapeutic Approach for the Management of Painful Chronic Temporomandibular Disorders (TMD)[NCT05162027] | Phase 2 | 5 participants (Actual) | Interventional | 2022-04-01 | Terminated (stopped due to Low enrollment rate) | ||
| Effect of COMT (Catecholamine-O-methyltransferase) Genetic Polymorphisms on Response to Propranolol Therapy in Temporomandibular Disorder[NCT02437383] | Phase 2 | 200 participants (Actual) | Interventional | 2015-08-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Propranolol ER | -3.3 |
| Placebo | 1.0 |
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | beats per minute (Least Squares Mean) |
|---|---|
| Propranolol ER | -3.9 |
| Placebo | 1.5 |
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.3 |
| Placebo | -0.8 |
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.9 |
| Placebo | -1.2 |
Measured at TMD exam. A higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm (Least Squares Mean) |
|---|---|
| Propranolol ER | 4.5 |
| Placebo | 1.4 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of lateral epicondyle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 41.4 |
| Placebo | 22.7 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of masseter muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/- 7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 38.3 |
| Placebo | 29.3 |
Pressure values, measured in kilopascals (kPa), from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporalis muscle, are averaged to obtain a single pressure pain threshold value per anatomical site. The range is 0-500 kPa and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 41.8 |
| Placebo | 38.4 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of temporomandibular joint, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 36.8 |
| Placebo | 25.3 |
Pressure values, measured in kilopascals, from up to 5 experimental pressure stimuli, bilaterally applied to the area of trapezius muscle, will be averaged to obtain a single pressure pain threshold value per anatomical site. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | kPa (Least Squares Mean) |
|---|---|
| Propranolol ER | 64.1 |
| Placebo | 63.3 |
Average of 3 repeated measures taken with a 2-minute interval. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| Propranolol ER | -3.6 |
| Placebo | 1.3 |
"The HIT-6 contains 6 items and assesses headache-related disability by the frequency of daily activity limitations ranging from never to always. The 6 item scores are summed to yield a global score ranging from 36 to 78. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -5.1 |
| Placebo | -3.1 |
"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.3 |
| Placebo | -0.7 |
"The HADS is a 14-item assessment of anxiety (7 items) and depression (7 items) using the relative frequency of symptoms over the past week, rated on a 4-point scale ranging from 0 = not at all to 3 = very often indeed. Responses are summed to provide separate scores for anxiety and depression with a range from 0 to 21. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.0 |
| Placebo | -0.6 |
"The JFLS contains 20 items that measure limitations across mastication, vertical jaw mobility, and verbal/emotional expression rated on a 0-10 scale where 0 = no limitation and 10 = severe limitation. The Global Score is computed as the mean response for all items and ranges from 0 to 10. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.1 |
| Placebo | -0.8 |
"The PSS assesses the frequency of 14 sources of stress on a scale from 0 = never to 4 = very often. The item scores are summed to yield a global score ranging from 0 to 56. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -2.6 |
| Placebo | -1.9 |
The PSQI has 19 items grouped into 7 component scores, each weighted equally on a 0-3 scale, The 7 component scores are summed to yield a global PSQI score, which has a range of 0-21. A higher score means a worse outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.7 |
| Placebo | -1.0 |
"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | 3.6 |
| Placebo | 2.8 |
"The SF-12v2 contains 7 questions assessing 8 domains of functioning and well-being rated from: excellent to poor (for general health); yes, limited a lot to no, not limited at all (for functional level); and all of the time to none of the time (for emotional state). These 8 domains can be further summarized into a physical component summary (PCS) and a mental component summary (MCS). summary (MCS). The range for each component is 0-100 and a higher score means a better outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | 1.2 |
| Placebo | 0.3 |
"The SF-McGill Pain Questionnaire contains 4 affective descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 12. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -2.9 |
| Placebo | -3.1 |
"Self-reported present intensity of facial pain at the moment of assessment scored on a descriptive scale where 1 = no pain' and 6 = excruciating pain. A higher score means worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.9 |
| Placebo | -0.7 |
"The SF-McGill Pain Questionnaire contains 11 sensory descriptors rated on a 0-3 scale where 0 = none, 1 = mild, 2 = moderate, and 3 = severe. The item scores are summed to yield a total score ranging from 0 to 33. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -1.9 |
| Placebo | -1.6 |
"Self-reported average facial pain duration for the last week scored on 0-100 percentage scale where percent = percent of waking day you had facial pain. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -23.6 |
| Placebo | -21.6 |
"Self-reported average facial pain intensity for the last week scored on 0-100 numerical rating scale where 0 = no pain and 100 = the most intense pain imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -18.2 |
| Placebo | -15.8 |
"Self-reported average fatigue for the last week scored on 0-100 numerical rating scale where 0 = no fatigue and 100 = the greatest imaginable. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -12.0 |
| Placebo | -11.4 |
"The SCL-90R Somatization Scale is a 12-item assessment of somatic symptom distress over the past 7 days rated from 0 = not at all to 4 = extremely. The scale score is computed as the mean for all items. The score range is from 0 to 4. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -0.2 |
| Placebo | -0.2 |
"Weekly mean pain duration computed as the arithmetic mean of daily pain duration values during the week prior to randomization and prior to each study visit. Daily pain duration is measured on 0-100 percentage scale where percent = percent of waking day you had facial pain as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -17.9 |
| Placebo | -16.6 |
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary and divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -13.9 |
| Placebo | -12.1 |
"Weekly mean pain intensity computed as the arithmetic mean of daily pain intensity values during the week prior to randomization and prior to each study visit. Daily pain intensity is measured on 0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) as reported in the Daily Symptom Diary. A higher score means a worse outcome." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| Propranolol ER | -17.1 |
| Placebo | -13.6 |
Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain threshold (temperature at which pain is first perceived). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | degrees Celsius (Least Squares Mean) |
|---|---|
| Propranolol ER | 1.3 |
| Placebo | 0.5 |
Temperature values, measured in degrees Celsius, from 4 examiner-applied contact heat stimuli will be averaged to measure the experimental thermal pain tolerance (temperature at which pain can no longer be tolerated). The range was 32-50 degrees Celsius and a higher value means a better outcome. (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | degrees Celsius (Least Squares Mean) |
|---|---|
| Propranolol ER | 0.5 |
| Placebo | 0.4 |
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) Low Pain Sensitive (LPS) haplotypes." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| 0 LPS haplotypes | 1 LPS haplotype | 2 LPS haplotypes | |
| Placebo | -12.3 | -13.2 | -2.5 |
| Propranolol ER | -14.2 | -12.2 | -15.2 |
"Weekly mean pain index computed as the arithmetic mean of daily pain index values during the week prior to randomization and prior to each study visit. Daily pain index is computed as pain intensity (0-100 numeric rating scale where 0 = no pain and 100 = the most intense pain imaginable) multiplied by pain duration (0-100 percentage scale where percent = percent of waking day you had facial pain) as reported in the Daily Symptom Diary, divided by 100. The pain index range is from 0 to 100. A higher score means a worse outcome. The pain index was stratified per number of catechol-O-methyltransferase (COMT) valine alleles at single nucleotide polymorphism (SNP) rs4680." (NCT02437383)
Timeframe: Visit 1 (study day 0) and Visit 4 (study day 63 +/-7)
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| 0 valine alleles | 1 valine allele | 2 valine alleles | |
| Placebo | -13.9 | -13.1 | -9.7 |
| Propranolol ER | -14.2 | -13.9 | -14.3 |
8 reviews available for propranolol and Alcohol Abuse
| Article | Year |
|---|---|
Noradrenergic targets for the treatment of alcohol use disorder.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antag | 2018 |
[Use of beta-adrenergic blockers in neurologic and psychiatric clinical practice].
Topics: Adrenergic beta-Antagonists; Alcoholism; Anti-Anxiety Agents; Cardiovascular Diseases; Humans; Hyper | 1981 |
The pharmacokinetics of psychotropic medication in the elderly: a review.
Topics: Aged; Alcoholism; Analgesics; Antidepressive Agents, Tricyclic; Barbiturates; Biological Availabilit | 1981 |
Antianxiety drugs in alcohol withdrawal.
Topics: Alcoholism; Anti-Anxiety Agents; Benzodiazepines; Ethanol; Haloperidol; Humans; Lithium; Propranolol | 1978 |
Propranolol in the treatment of alchoholism: a review.
Topics: Alcoholism; Cardiac Output; Humans; Propranolol; Stress, Psychological; Substance Withdrawal Syndrom | 1976 |
Treatment of the cardiomyopathies.
Topics: Adrenergic beta-Antagonists; Alcoholism; Angina Pectoris; Anticoagulants; Atrial Fibrillation; Blood | 1973 |
Use of beta-adrenergic receptor blocking drugs in psychiatry.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alcoholism; Anxiety; Chlordiazepoxide; Di | 1974 |
Beta-adrenergic receptor blocking drugs in psychiatry.
Topics: Acute Disease; Adrenergic beta-Antagonists; Alcoholism; Amphetamine; Animals; Antidepressive Agents; | 1974 |
12 trials available for propranolol and Alcohol Abuse
| Article | Year |
|---|---|
Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Propranolol; Temporomandibular Joint Disorders; Tre | 2020 |
Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Propranolol; Temporomandibular Joint Disorders; Tre | 2020 |
Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Propranolol; Temporomandibular Joint Disorders; Tre | 2020 |
Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.
Topics: Alcoholism; Double-Blind Method; Female; Humans; Propranolol; Temporomandibular Joint Disorders; Tre | 2020 |
Propranolol treatment in chronic alcoholic outpatients.
Topics: Adult; Aged; Alcoholism; Ambulatory Care; Clinical Trials as Topic; Double-Blind Method; Female; Hum | 1981 |
Propranolol versus diazepam in the management of the alcohol withdrawal syndrome: double-blind controlled trial.
Topics: Adult; Aged; Alcohol Withdrawal Delirium; Alcoholism; Diazepam; Double-Blind Method; Humans; Male; M | 1994 |
Letter: Propranolol-decreased noradrenaline excretion and alcohol withdrawal.
Topics: Alcoholism; Dose-Response Relationship, Drug; Humans; Male; Norepinephrine; Placebos; Propranolol; S | 1976 |
[Indications for beta-blockers in neurology].
Topics: Alcoholism; Antiparkinson Agents; Anxiety; Clinical Trials as Topic; Drug Therapy, Combination; Huma | 1978 |
Effect of propranolol on acute withdrawal tremor in alcoholic patients.
Topics: Acute Disease; Adult; Age Factors; Aged; Alcoholism; Clinical Trials as Topic; Drug Evaluation; Fema | 1976 |
A comparison of the effects of propranolol and diazepam in alcoholics.
Topics: Adult; Alcoholism; Anxiety Disorders; Clinical Trials as Topic; Depression; Diazepam; Humans; Male; | 1976 |
Beta-adrenergic receptor blocking drugs in psychiatry.
Topics: Acute Disease; Adrenergic beta-Antagonists; Alcoholism; Amphetamine; Animals; Antidepressive Agents; | 1974 |
A controlled evaluation of propranolol in chronic alcoholic patients presenting the symptomatology of anxiety and tension.
Topics: Adult; Alcoholism; Anxiety; Clinical Trials as Topic; Female; Humans; Male; Placebos; Propranolol; P | 1973 |
Propranolol and behavior of alcohol addicts after acute alcohol ingestion.
Topics: Adult; Alcoholism; Analysis of Variance; Attention; Behavior; Body Weight; Breath Tests; Clinical Tr | 1974 |
Psychopharmacology.
Topics: Alcoholism; Anxiety; Brain Damage, Chronic; Chronic Disease; Clinical Trials as Topic; Depression; E | 1970 |
The psychological effects of propranolol in the abstinence phase of chronic alcoholics.
Topics: Adult; Alcoholism; Anxiety; Chlormethiazole; Chronic Disease; Clinical Trials as Topic; Diazepam; Hu | 1971 |
38 other studies available for propranolol and Alcohol Abuse
| Article | Year |
|---|---|
The role of beta- and alpha-adrenergic receptors on alcohol drinking.
Topics: Alcohol Drinking; Alcoholism; Animals; Betaxolol; Humans; Male; Norepinephrine; Propranolol; Rats; R | 2023 |
Refractory hepatic encephalopathy in a patient with hypothyroidism: Another element in ammonia metabolism.
Topics: Adrenergic beta-Antagonists; Alcoholism; Ammonia; Antithyroid Agents; Brain; Carbimazole; Diagnosis, | 2017 |
Noradrenergic β-receptor antagonism in the basolateral amygdala impairs reconsolidation, but not extinction, of alcohol self-administration: Intra-BLA propranolol impairs reconsolidation of alcohol self-administration.
Topics: Adrenergic beta-Antagonists; Alcoholism; Animals; Basolateral Nuclear Complex; Conditioning, Operant | 2018 |
Combining the α1 -adrenergic receptor antagonist, prazosin, with the β-adrenergic receptor antagonist, propranolol, reduces alcohol drinking more effectively than either drug alone.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-Antagonists; Alcohol Drinking; Alcoholism; | 2014 |
Essential tremor leading to toxic liver damage successfully treated with deep brain stimulation.
Topics: Adrenergic beta-Antagonists; Aged; Alcoholism; Anticonvulsants; Central Nervous System Depressants; | 2009 |
Effects of β-adrenoceptor antagonists on alcohol drinking by alcohol-dependent rats.
Topics: Adrenergic beta-Antagonists; Alcohol Drinking; Alcoholism; Animals; Behavior, Animal; Conditioning, | 2010 |
Beta-adrenergic coupled phospholipid methylation. A possible role in withdrawal from chronic ethanol.
Topics: Alcoholism; Animals; Cerebral Cortex; Epinephrine; Ethanol; Humans; Isoproterenol; Kinetics; Male; M | 1984 |
[Effect of central effective substances on alcohol preference].
Topics: Alcohol Drinking; Alcoholism; Animals; Arecoline; Atropine; Central Nervous System Stimulants; Cypro | 1983 |
[Beta adrenergic inhibitors in the treatment of chronic alcoholism].
Topics: Adrenergic beta-Antagonists; Alcoholism; Humans; Propranolol | 1984 |
Beta-adrenergic receptors in chronic alcoholic rat hearts.
Topics: Alcoholism; Animals; Binding, Competitive; Humans; Isoproterenol; Male; Myocardium; Propranolol; Rat | 1982 |
Essential tremor: a risk factor for alcoholism?
Topics: Alcohol Drinking; Alcoholism; Humans; Male; Middle Aged; Propranolol; Risk; Tremor | 1984 |
Metabolic interactions of aldehyde dehydrogenase with therapeutic and toxic agents.
Topics: Alcohol Oxidoreductases; Alcoholism; Aldehyde Dehydrogenase; Aldehyde Oxidoreductases; Animals; Anti | 1982 |
Disturbed alpha-adrenergic modulation of insulin and growth hormone secretion in chronic alcoholics.
Topics: Adult; Alcoholism; Blood Glucose; Epinephrine; Female; Growth Hormone; Humans; Insulin; Insulin Secr | 1980 |
Propranolol and chlordiazepoxide effects on cardiac arrhythmias during alcohol withdrawal.
Topics: Alcoholism; Arrhythmias, Cardiac; Chlordiazepoxide; Electroencephalography; Humans; Male; Propranolo | 1980 |
The effect of propranolol on the electroencephalogram in normal and ethanol dependent rats.
Topics: Alcoholism; Animals; Brain; Electroencephalography; Humans; Male; Propranolol; Rats; Substance Withd | 1980 |
Suppression of splenic natural killer cell activity in a mouse model for binge drinking. II. Role of the neuroendocrine system.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Alcoholism; Animals; Azides; Benzodiazepi | 1996 |
Changes in receptor sensitivity of the cerebral cortex and liver during chronic ethanol ingestion and withdrawal.
Topics: Alcoholism; Animals; Brain; Cyclic AMP; Humans; Liver; Male; Norepinephrine; Propranolol; Rats; Rece | 1977 |
Traumatic hemobilia: a complication of percutaneous liver biopsy.
Topics: Adult; Alcoholism; Bile; Biliary Tract Diseases; Biopsy, Needle; Blood; Chemical and Drug Induced Li | 1977 |
Transient suppression of growth hormone secretion after chronic ethanol intake.
Topics: Adult; Alcoholism; Blood Glucose; Depression, Chemical; Ethanol; Glucagon; Growth Hormone; Humans; I | 1978 |
Evidence for parallel development of tolerance to the hyperactivating and discoordinating effects of ethanol.
Topics: Alcoholic Intoxication; Alcoholism; Amphetamine; Animals; Chlorpromazine; Drug Tolerance; Ethanol; H | 1977 |
The nature and etiology of normal and alcohol withdrawal tremor.
Topics: Alcoholism; Biomechanical Phenomena; Electromyography; Female; Humans; Male; Posture; Propranolol; S | 1979 |
Cerebral blood flow and oxygen consumption during ethanol withdrawal in the rat.
Topics: Adrenal Glands; Adrenalectomy; Alcoholism; Animals; Brain; Carbon Dioxide; Cerebrovascular Circulati | 1979 |
Comparative efficacy of propranolol and chlordiazepoxide in alcohol withdrawal.
Topics: Adult; Alcoholism; Catecholamines; Chlordiazepoxide; Dose-Response Relationship, Drug; Drug Evaluati | 1977 |
Alcohol intoxication and the alcohol withdrawal syndrome.
Topics: Alcoholic Intoxication; Alcoholism; Benzodiazepines; Chlordiazepoxide; Hallucinations; Humans; Pheny | 1978 |
Proceedings: Abstinence: goal for rehabilitation.
Topics: Alcohol Drinking; Alcoholism; Compulsive Behavior; Ethanol; Goals; Humans; Motivation; Propranolol; | 1976 |
[Propranolol in the treatment of withdrawal symptoms].
Topics: Adult; Alcoholism; Female; Humans; Male; Propranolol; Substance Withdrawal Syndrome; Substance-Relat | 1975 |
[Slow leg tremor].
Topics: Adult; Aged; Alcoholism; Follow-Up Studies; Humans; Leg; Levodopa; Male; Middle Aged; Propranolol; T | 1975 |
Letter: Effect of propranolol on tremor of alcohol withdrawal.
Topics: Alcoholism; Humans; Propranolol; Substance Withdrawal Syndrome; Tremor | 1976 |
The antiinflammatory effect of dopamine in alcoholic hemorrhagic pancreatitis in cats. Studies on the receptors and mechanisms of action.
Topics: Acute Disease; Alcoholism; Animals; Capillary Permeability; Cats; Dopamine; Ethanol; Haloperidol; He | 1991 |
[Effectiveness of single intravenous administration of cordarone, ethacizine and obsidan in ventricular extrasystole in patients with chronic alcoholism during withdrawal].
Topics: Adult; Alcoholism; Amiodarone; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Ethanol; Humans | 1991 |
Effects of acetaldehyde condensation products on human platelet aggregation.
Topics: Acetaldehyde; Adenosine Diphosphate; Alcoholism; Carbolines; Epinephrine; Ethanol; Humans; In Vitro | 1987 |
Propranolol in alcohol addiction.
Topics: Adrenergic beta-Antagonists; Alcoholism; Female; Humans; Propranolol; Substance Withdrawal Syndrome | 1972 |
Beta-blockade for withdrawal symptoms?
Topics: Adrenergic beta-Antagonists; Alcoholism; Humans; Propranolol; Substance Withdrawal Syndrome | 1973 |
[Apomorphine and propranolol in the treatment of alcoholism].
Topics: Alcoholism; Apomorphine; Diazepam; Humans; Propranolol | 1974 |
Ethanol, acetaldehyde, and myocardial protein synthesis.
Topics: Acetaldehyde; Albumins; Alcoholism; Animals; Carbon Isotopes; Depression, Chemical; Ethanol; Guinea | 1972 |
Inderal (propranolol) in the treatment of alcoholism.
Topics: Adult; Alcoholism; Anxiety; Humans; Propranolol; Substance Withdrawal Syndrome; Tremor | 1973 |
[Clinical use of propranolol].
Topics: Alcoholism; Angina Pectoris; Aortic Aneurysm; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flut | 1974 |
Selective arterial drug infusions in the treatment of acute gastrointestinal bleeding. A preliminary report.
Topics: Acute Disease; Adult; Aged; Alcoholism; Animals; Colitis; Colitis, Ulcerative; Diverticulum, Colon; | 1970 |